International Journal of Hematology

, Volume 89, Issue 1, pp 34–38 | Cite as

Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience

  • Shuqing Lü
  • Jianmin Wang
  • Xiaoqian Xu
  • Xiong Ni
  • Chongmei Huang
  • Huiying Qiu
  • Xiaoxia Hu
  • Jianmin Yang
Original Article


The aim of the present study was to evaluate the effectiveness of bortezomib combined with epirubicin, dexamethasone, and thalidomide (BADT) for the treatment of multiple myeloma (MM). The BADT regimen consisted of a maximum of eight 4-week cycles of: intravenous bortezomib (1.0 mg/m2) and intravenous epirubicin (12 mg/m2) on days 1, 4, 8, and 11; dexamethasone (20 mg) on days 1, 2, 4, 5, 8, 9, 11, and 12; and oral thalidomide (100 mg/m2) on days 1–28. Twelve patients with MM were included in the study, of whom four had not been previously treated and eight had been previously treated with at least one cycle of a systemic combined regimen. All the patients completed at least two cycles of treatment, with an average of five cycles; the complete response (CR) rate was 83.3% (10/12) and stabilization of disease was 16.7% (2/12). The average number of cycles required to achieve CR was 1.9 (range 1–6). In three patients, mobilization of peripheral blood stem cells allowed a sufficient quantity of CD34+ cells to be harvested for future autotransplantation. The main adverse reactions included peripheral neuropathy (4/12), thrombocytopenia (3/12), electrocardiographic abnormalities (4/12), neutropenia (5/12), and liver function impairment (4/12), primarily grade I–II. Infection occurred in four patients with neutropenia, including one patient who developed sepsis. The estimated 1-year overall survival rate was 91.7 ± 8.0%, and the estimated 1-year disease-free survival was 75.0 ± 12.5%. BADT is a highly effective combined regimen, with acceptable toxicity, for the treatment of multiple myeloma.


Multiple myeloma Bortezomib Epirubicin Dexamethasone Thalidomide 


  1. 1.
    Sharma NL, Sharma VC, Mahajan VK, Shanker V, Ranjan N, Gupta M. Thalidomide: an experience in therapeutic outcome and adverse reactions. J Dermatolog Treat. 2007;21:1–6.Google Scholar
  2. 2.
    Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001;12:991–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071–6.PubMedGoogle Scholar
  4. 4.
    Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136–44.PubMedGoogle Scholar
  5. 5.
    Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.PubMedCrossRefGoogle Scholar
  7. 7.
    Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–901.PubMedCrossRefGoogle Scholar
  8. 8.
    Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Rosiñol L, Oriol A, Mateos MV, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol. 2007;25:4452–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Freimann H, Calderoni A, Cornu P, Olie R. Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland. Swiss Med Wkly. 2007;137:317–22.PubMedGoogle Scholar
  11. 11.
    Biehn SE, Moore DT, Voorhees PM, et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2007;86:211–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology. 2007;12:235–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138:330–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Badros A, Goloubeva O, Fenton R, et al. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Clin Lymphoma Myeloma. 2006;7:210–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767–72.PubMedGoogle Scholar
  17. 17.
    Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Ciolli S, Leoni F, Gigli F, Rigacci L, Bosi A. Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients. Leuk Lymphoma. 2006;47:171–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007;110:1042–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Tong Y, Qian J, Li Y, Meng H, Jin J. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol. 2007;82:403–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Enrico O, Gabriele B, Nadia C, et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol. 2007;138:396–7.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2008

Authors and Affiliations

  • Shuqing Lü
    • 1
  • Jianmin Wang
    • 1
  • Xiaoqian Xu
    • 1
  • Xiong Ni
    • 1
  • Chongmei Huang
    • 1
  • Huiying Qiu
    • 1
  • Xiaoxia Hu
    • 1
  • Jianmin Yang
    • 1
  1. 1.Department of Hematology, Changhai HospitalSecond Military Medical UniversityShanghaiChina

Personalised recommendations